Trial Profile
A multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in Her-2 negative metastatic breast cancer (MBC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2015
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Capecitabine
- Indications Breast cancer
- Focus Therapeutic Use
- 22 May 2014 New trial record